Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Reaffirmed by Needham & Company LLC

Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “hold” rating restated by investment analysts at Needham & Company LLC in a report released on Tuesday, Benzinga reports.

Other equities research analysts have also issued research reports about the company. Wells Fargo & Company upped their target price on Neurocrine Biosciences from $127.00 to $140.00 and gave the company an “equal weight” rating in a research report on Thursday, February 8th. Wedbush restated an “outperform” rating and set a $147.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, April 17th. JPMorgan Chase & Co. increased their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Citigroup cut their price target on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a report on Thursday, February 8th. Finally, StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $142.38.

Neurocrine Biosciences Trading Down 0.8 %

NASDAQ NBIX opened at $138.97 on Tuesday. The business’s 50-day moving average price is $136.48 and its two-hundred day moving average price is $127.62. Neurocrine Biosciences has a 12 month low of $89.04 and a 12 month high of $148.37. The firm has a market capitalization of $13.83 billion, a PE ratio of 57.43 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. During the same quarter in the prior year, the company earned $0.88 EPS. The firm’s revenue for the quarter was up 25.0% compared to the same quarter last year. As a group, analysts forecast that Neurocrine Biosciences will post 4.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider David W. Boyer sold 456 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total transaction of $64,733.76. Following the sale, the insider now directly owns 4,894 shares in the company, valued at $694,752.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Neurocrine Biosciences news, insider David W. Boyer sold 456 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total value of $64,733.76. Following the sale, the insider now directly owns 4,894 shares in the company, valued at $694,752.24. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Ingrid Delaet sold 5,000 shares of the business’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the completion of the sale, the insider now owns 7,507 shares in the company, valued at $1,088,965.42. The disclosure for this sale can be found here. Over the last three months, insiders have sold 186,994 shares of company stock worth $25,806,409. 4.60% of the stock is owned by company insiders.

Institutional Trading of Neurocrine Biosciences

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Neurocrine Biosciences by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company’s stock valued at $1,279,433,000 after purchasing an additional 150,485 shares in the last quarter. DSM Capital Partners LLC grew its position in shares of Neurocrine Biosciences by 15.4% in the third quarter. DSM Capital Partners LLC now owns 1,224,017 shares of the company’s stock valued at $137,702,000 after purchasing an additional 163,747 shares in the last quarter. Brown Advisory Inc. grew its position in shares of Neurocrine Biosciences by 2.2% in the fourth quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock valued at $146,703,000 after purchasing an additional 23,831 shares in the last quarter. Braidwell LP grew its position in shares of Neurocrine Biosciences by 3.7% in the third quarter. Braidwell LP now owns 968,024 shares of the company’s stock valued at $108,903,000 after purchasing an additional 34,662 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in shares of Neurocrine Biosciences by 66.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock valued at $121,007,000 after purchasing an additional 364,986 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.